Co-Diagnostics, Inc.
- Jurisdiction
United States - LEI
549300Z1JPESYWFM1R93 - ISIN
US1897631057 (CODX )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
3
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
3
/ 7
Profile
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. Read full profile
Fundamentals
- Net revenue
€856.07K - Gross margin
39.6% - EBIT
-€33.05M - EBIT margin
-3,861.1% - Net income
-€30.70M - Net margin
-3,586.0%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
No insider transactions in the last 90 days. View older insider transactions
Earnings Calls
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |
Earnings Calls
Latest earnings call: May 9, 2024 (Q1 2024)